Table 2.
Number of events and adjusted hazard ratios between warfarin users and nonusers among patients with hyperthyroidism-related atrial fibrillation.
| After PSM | |||
|---|---|---|---|
| Warfarin Users | Warfarin Nonusers | p Value | |
| N = 90 | N = 168 | ||
| Stroke/TIA | |||
| Events (%) | 19 (21.1) | 21 (12.5) | 0.069 |
| Mean follow-up time (months, SD) | 79.8 (43.1) | 86.0 (41.1) | 0.254 |
| aHR (95% CI) a | 1.16 (0.52–2.56) | Reference | 0.717 |
| Major bleeding | |||
| Events (%) | 39 (43.3) | 64 (38.1) | 0.413 |
| Mean follow-up time (months, SD) | 65.0 (45.5) | 65.3 (43.7) | 0.958 |
| aHR (95% CI) b | 0.91 (0.56–1.47) | Reference | 0.702 |
Abbreviations: CI, confidence interval; PSM, propensity score matching; SD, standard deviation; TIA, transient ischemic attack. a Adjusted for age, gender, CHA2DS2-VASc, hypertension, congestive heart failure, peripheral vascular disease, diabetes mellitus, and aspirin. b Adjusted for age, gender, CHA2DS2-VASc, hypertension, congestive heart failure, diabetes mellitus, chronic obstructive pulmonary disease, hyperlipidemia, aspirin, and statins.